Advanced Age Management

04/26/2026

Recent scientific research has been examining how chronically elevated cortisol, the body’s primary stress hormone, can affect multiple systems over time. Studies suggest that prolonged high cortisol levels may contribute to increased muscle protein breakdown, reduced recovery, and gradual loss of lean muscle mass.

This process can potentially impact skeletal muscles throughout the body, including areas that support the hips, which may be associated with weakness, stiffness, or reduced mobility when combined with inactivity or other health conditions. However, claims that doctors miss this connection 83 percent of the time are not supported by strong clinical evidence and should be interpreted cautiously.

Medical experts emphasize that persistent pain or weakness should be properly evaluated, as multiple factors including posture, injury, inflammation, and hormonal balance may be involved, and stress management can support overall health.

Evidence based approaches such as regular physical activity, adequate sleep, balanced nutrition, and mindfulness practices are commonly associated with healthier cortisol regulation.

04/26/2026

Recent research shows a single nutrient—dietary fiber—mimics the anti-aging benefits of fasting and calorie restriction at the genetic level, even when people eat more food.
Gene expression studies found that high-fiber diets produced similar longevity signatures to fasting, despite higher overall calorie and protein consumption.
While human studies directly comparing fiber to fasting remain limited, overwhelming epidemiological evidence links higher fiber intake to reduced mortality and better health outcomes including cardiovascular protection and metabolic improvements.
For most people, boosting fiber intake offers a practical, sustainable alternative to restrictive dieting approaches.
Learn more about the science and practical ways to increase your daily fiber consumption in the full article.

04/26/2026

Paper filters best for health in coffee drinkers

Coffee's effect on your cholesterol depends on what catches the diterpenes before they reach your cup.

Coffee beans contain two natural compounds called diterpenes: cafestol and kahweol. They aren't oils themselves, but they ride along in coffee oil, the lipid fraction of the bean. When hot water passes through ground coffee, those diterpenes get carried into the brew on tiny lipid droplets. Once swallowed and absorbed, cafestol acts on your liver. It activates a receptor called FXR, which suppresses an enzyme called CYP7A1. CYP7A1 is the enzyme your liver uses to convert cholesterol into bile acids. With less of that conversion happening, your liver clears less LDL out of circulation, so blood LDL rises.

This is not a fringe finding. It has been replicated across decades of randomized controlled trials. Jee and colleagues (2001, American Journal of Epidemiology) pooled fourteen RCTs and found a clear pattern: unfiltered coffee raised total and LDL cholesterol in a dose-dependent way, while filtered coffee showed essentially no effect. Cai and colleagues (2012, European Journal of Clinical Nutrition) pooled twelve more RCTs in 1,017 subjects and found coffee raised LDL by an average of 5.4 mg/dL, with the largest effects in trials using unfiltered coffee.

The variable that determines whether you get a cup full of diterpenes or a cup that has had them stripped out is the filter material. Paper traps them. Metal mesh, the kind you'll find in a French press, an espresso basket, a percolator, or a moka pot, does not. A 2025 analysis of Swedish workplace coffee (Orrje et al., Nutrition, Metabolism and Cardiovascular Diseases) measured cafestol concentrations across brewing methods. Boiled coffee came in at 939 mg/L. Workplace brewing machines averaged 176 mg/L. French press and percolator landed around 90 mg/L. Some espresso samples reached 2,447 mg/L. Paper-filtered home drip averaged 12 mg/L. The same green coffee bean produces wildly different cardiovascular exposures depending on what comes between the grounds and your cup.

The downstream evidence comes from a 20-year prospective study of 508,747 Norwegian adults (Tverdal et al., 2020, European Journal of Preventive Cardiology). Adults who drank filtered coffee had about 15% lower all-cause mortality compared with non-drinkers. Unfiltered coffee drinkers showed a weaker, less consistent benefit. In adults drinking nine or more unfiltered cups per day, ischemic heart disease mortality was modestly elevated.

A few honest caveats. Cafestol's LDL-raising effect is real and reproducible, but the magnitude is moderate, not dramatic. A 5 mg/dL bump in LDL over years matters more for someone with elevated baseline cholesterol or established cardiovascular risk than for someone whose lipids are already excellent. Cloth filters, properly used, also remove a substantial fraction of diterpenes. And coffee carries other compounds: chlorogenic acids, polyphenols, caffeine, and trigonelline have their own metabolic effects, mostly favorable. These compounds are mostly water-soluble. Paper filters trap the lipid-soluble diterpenes while letting the water-soluble actors pass through.

Practically: if you have a family history of hypercholesterolemia, an existing LDL concern, or you're already managing cardiovascular risk, the brewing method is one of the easier levers. Switching from a French press to a pour-over with a paper filter changes nothing about caffeine, ritual, or flavor in any meaningful way. It just removes the diterpenes from the cup.
The bean isn't the variable. The filter is.

Jee et al., American Journal of Epidemiology, 2001
Cai et al., European Journal of Clinical Nutrition, 2012
Tverdal et al., European Journal of Preventive Cardiology, 2020
Orrje et al., Nutrition Metabolism and Cardiovascular Diseases, 2025

04/24/2026

We definitely need more human data, both safety & efficacy.

04/22/2026

04/19/2026

The Q-SYMBIO trial, published in JACC: Heart Failure in 2014, is the most important study ever conducted on CoQ10 supplementation and cardiovascular outcomes. It is also a trial that most people promoting CoQ10 supplements seem to have selectively forgotten the details of.

Mortensen and colleagues enrolled 420 patients with moderate to severe chronic heart failure across 17 cardiology centers in nine countries. Half received 100mg of ubiquinone three times daily for two years as adjunct to standard heart failure therapy. The other half received matching placebo. The primary endpoint was a composite of unplanned heart failure hospitalization, cardiovascular death, urgent transplant, or need for mechanical support. Patients entered this trial already on guideline-directed medical therapy. The intervention was added on top of optimal care, not instead of it.

The results at two years: 15% of patients in the CoQ10 group hit the primary endpoint versus 26% in the placebo group. A 43% relative reduction in serious cardiac events. Cardiovascular mortality was 9% in the CoQ10 arm versus 16% in placebo, a 44% relative reduction. All-cause mortality was 10% versus 18%. Heart failure hospitalizations were 8% versus 14%. Every clinically meaningful endpoint moved in the same direction by similar magnitudes. This is the kind of effect size that earns a drug a breakthrough designation. It was achieved with a molecule that has been sold as a dietary supplement for decades.

The mechanism is not a mystery. CoQ10 is the electron shuttle that moves electrons from Complex I and Complex II to Complex III in the mitochondrial respiratory chain. That electron flow drives the proton gradient across the inner mitochondrial membrane, which powers ATP synthesis. No other molecule in human biology can perform this function. When myocardial CoQ10 is depleted, which occurs in heart failure and is worsened by statin use via the mevalonate pathway, cardiac mitochondrial efficiency drops. Myocardial CoQ10 levels correlate with heart failure severity. The CoQ10 deficit tracks with how sick the heart is.

The Q-SYMBIO finding was independently replicated by KiSel-10 (Alehagen et al., 2013), a Swedish trial in 443 elderly community-dwelling subjects given 200mg CoQ10 (ubiquinone) plus 200μg selenium daily for four years. Cardiovascular mortality dropped from 12.6% in the placebo arm to 5.9% in the treatment arm. The twelve-year follow-up published in 2018 showed the mortality benefit was sustained long after the intervention ended, which is an unusual and striking finding. Two independent trials. Two different patient populations. Both using ubiquinone. Both showing large reductions in cardiovascular death.

Here is the part the marketing departments would rather you not notice. Both trials used ubiquinone, the oxidized form of CoQ10, specifically the Bio-Quinone product sold under the Myoqinon brand name. Not ubiquinol. Every major clinical trial demonstrating hard cardiovascular outcomes from CoQ10 supplementation used the form that retails for a fraction of the price of "premium" ubiquinol products. Fladerer and Grollitsch published a systematic review in Current Cardiology Reports in 2023 that reviewed 28 clinical trials and found no ubiquinol trial has replicated these cardiovascular mortality findings. They explicitly recommend ubiquinone over ubiquinol for the prevention and treatment of cardiovascular disease in heart failure patients.

Why did it work? The formulation was not accidental. Bio-Quinone is crystal-dispersed ubiquinone delivered in a soft gel with a carrier oil. Crystal dispersion is the manufacturing step that breaks CoQ10 out of its native crystalline lattice so it can actually dissolve in gastrointestinal fluid. Without it, oral bioavailability drops by roughly 75% (Mantle and Dybring, Antioxidants, 2020). The soft gel with oil carrier ensures lipid-phase absorption. Three times daily dosing maintains serum levels above the approximately 3 μg/mL therapeutic threshold commonly cited in the CoQ10 cardiovascular literature. The trial worked because the formulation worked. Not because the form on the label was special.

The practical takeaways: if you or someone you care about has heart failure, CoQ10 has the strongest evidence base of any dietary intervention for reducing cardiovascular death. The dose is 100mg three times daily, ideally with meals, as ubiquinone in a crystal-dispersed soft gel. Cheaper forms without crystal dispersion do not produce the same bioavailability. Neither does ubiquinol at standard doses, despite the marketing. Talk to a cardiologist before starting. If you are on warfarin, CoQ10 can alter INR and requires monitoring. This is adjunct therapy, not a replacement for guideline-directed medical care.

The broader point for the dietary supplement industry is this. When the best-designed trial on a supplement outperforms most pharmaceutical interventions in its target population, the industry should probably be shouting about it from the rooftops. Instead, the field pivoted to selling a more expensive form that has not replicated the outcome data, while the cheaper form that generated the evidence base sits in the background. Formulation science beat redox chemistry. The market has the story backwards.

Mortensen, JACC HF, 2014
Alehagen, Int J Cardiol, 2013
Fladerer & Grollitsch, Curr Cardiol Rep, 2023
Mantle & Dybring, Antioxidants, 2020

04/19/2026

Most of the protein timing conversation online is stuck arguing about an anabolic window that barely exists. The actual evidence has been clear for over a decade. Total daily protein intake is the dominant variable that drives muscle outcomes, whether you're a 25-year-old trying to add mass or a 70-year-old trying to preserve what you have. Distribution across the day matters modestly.

Precise timing around workouts matters very little.
The mechanism is straightforward. Resistance training stimulates muscle protein synthesis, and that elevated synthesis state lasts for at least 24 hours, not 30 or 60 minutes. Each protein-containing meal produces a synthesis pulse on top of that elevated baseline. The per-meal threshold exists because synthesis is triggered primarily by leucine reaching roughly 2 to 3 grams per meal. In younger adults, this requires about 20 to 25 grams of high-quality protein per meal. In older adults, anabolic resistance raises the bar considerably, and roughly 35 to 40 grams per meal is needed to produce the same synthesis response. Below the threshold, the pulse is blunted. Above it, returns diminish rapidly.

The meta-analytic evidence is unusually strong for a nutrition question. Morton and colleagues pooled 49 randomized controlled trials across 1,863 adults of varying ages and training backgrounds and found that protein supplementation increases lean body mass and strength in a dose-dependent fashion up to about 1.62 grams per kilogram per day. Beyond that, the curve flattens. This plateau held across trained and untrained participants. Age reduced the response, which means older adults need more protein to get the same effect, not less. This is the anabolic resistance of aging, and it is the reason the lower end of the adequate intake range is inadequate for most adults over 60.

Distribution does matter, but modestly and within a reasonable window. Areta and colleagues used a controlled 12-hour feeding study in trained men to compare three patterns of protein delivery following resistance exercise. Eight smaller doses every 90 minutes, four moderate doses every three hours, or two large doses every six hours. The intermediate pattern, roughly 20 grams every three hours, produced the highest myofibrillar protein synthesis over the 12 hours. Too-frequent small doses under-trigger the synthesis response by failing to cross the leucine threshold. Too-spaced large doses leave long gaps where the system isn't being stimulated. Three to five meals per day, each containing enough protein to hit the per-meal threshold, is the pattern the evidence points to.
The post-workout "window" question has been directly tested. Schoenfeld and colleagues randomly assigned 21 resistance-trained men to consume 25 grams of protein either immediately before or immediately after resistance exercise over 10 weeks. Strength, hypertrophy, and body composition were equivalent between groups. The time before and after training, roughly an hour or two on each side, should be thought of as a slow dimmer rather than a light switch. If your pre-workout meal contained adequate protein, the "post-workout" stimulus is already running when you finish your last set.

Practically, the numbers that matter for adults trying to build or maintain muscle are these. Daily total of 1.6 to 2.2 grams per kilogram of body weight, with older adults reliably benefiting from the upper end of that range due to anabolic resistance. Per meal, the younger end of the per-meal target is 20 to 25 grams of high-quality protein. The older end is 35 to 40 grams. Three to five feedings distributed across the day is the pattern that maintains synthesis pulses without under- or over-dosing. Pre-sleep casein at 30 to 40 grams has evidence for overnight synthesis benefit, particularly in older and sarcopenic populations. Recent work suggests the pre-sleep effect is smaller than originally proposed when 24-hour total is already adequate, so treat it as useful for older adults and optional for younger adults hitting their numbers during the day. Whole food sources satisfy all of the above.

Supplementation is convenience, not magic.
A few common mistakes this framework prevents. Skipping breakfast and cramming 70 grams of protein into one late-afternoon meal plateaus your stimulus curve. Drinking a 10-gram protein shake every 90 minutes under-triggers each synthesis pulse and wastes amino acids. Panicking because you didn't consume protein within 30 minutes of training misses the point entirely. You have hours, not minutes.

The anabolic resistance note is the most underdiscussed piece of this. Older adults maintaining muscle mass are fighting a biological gradient. Their per-meal leucine threshold rises with age. Their baseline synthesis response blunts. The same 20-gram dose that drives a strong synthesis pulse in a 30-year-old produces a weaker response in a 70-year-old. The practical implication is that the 0.8 grams per kilogram RDA, published by the Institute of Medicine and still listed on food labels, is a floor for preventing deficiency in sedentary adults, not a target for muscle preservation. Adults over 60 trying to maintain strength and function should anchor around 1.8 to 2.2 grams per kilogram distributed across at least three solid protein meals daily, with per-meal doses near 35 to 40 grams to cross their elevated leucine threshold.

What the industry has monetized for 30 years is a narrow window that barely exists. What the evidence actually supports is unglamorous. Hit your total. Distribute it reasonably. Cross the per-meal leucine threshold, which rises with age. Emphasize quality protein from whole food sources. Age adjusts the dose upward, not downward.

Sources:
- Jäger R, et al. J Int Soc Sports Nutr. 2017;14:20.
- Morton RW, et al. Br J Sports Med. 2018;52(6):376-384.
- Schoenfeld BJ, et al. PeerJ. 2017;5:e2825.
- Areta JL, et al. J Physiol. 2013;591(9):2319-31.
- Moore DR, et al. Am J Clin Nutr. 2009;89(1):161-168.
- Witard OC, et al. Am J Clin Nutr. 2014;99(1):86-95.

04/16/2026

Old-school Soviet wrestlers knew exactly what they were doing!

Their programmes leaned heavily on kettlebells to build serious endurance and conditioning – methods that still hold up today.

One move that stands out: the deficit high pull, a brutal but effective way to develop power, grip and stamina in one go. Here's how to do it.

04/07/2026

In a fitness world obsessed with shredded physiques, Mark’s experience illustrates how medically prescribed TRT can restore mental clarity and energy rather than inflate muscle mass.

He spent 18 months on TRT without ever stepping foot in a gym, yet he maintained emotional resilience, improved his relationship, and tackled life’s curveballs with renewed motivation.

His story highlights a growing divide between high-dose bodybuilding protocols and medically supervised treatment for men who feel “off” but aren’t chasing performance gains.

By framing TRT as a lifeline for everyday function, not a shortcut to gym selfies, Mark challenges the stigma and invites deeper conversations about hormone health.

04/07/2026

HBOT has produced measurable, replicable effects on specific aging biomarkers in controlled studies. Dismissing HBOT as fringe would be a mistake.